Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC), patritumab deruxtecan, for treating EGFR-mutated non-small cell lung cancer...

AZN : 79.14 (+0.71%)
PFE : 29.75 (+0.08%)
MRK : 117.42 (-1.03%)
LLY : 905.80 (+0.09%)
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

There's a lot of hope for ivonescimab, but are investors being a bit too bullish?

MRK : 117.42 (-1.03%)
SMMT : 24.22 (-1.38%)
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond.

MRK : 117.42 (-1.03%)
PFE : 29.75 (+0.08%)
MRNA : 69.68 (-0.26%)
VRTX : 479.58 (+1.14%)
VKTX : 67.41 (+4.59%)
Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?

Summit Therapeutics is a clinical-stage biotech company that has returned over 1,100% in 2024. Is the stock still a good buy right now?

SMMT : 24.22 (-1.38%)
MRK : 117.42 (-1.03%)
C : 61.77 (+3.12%)
Where Will Merck Stock Be in 5 Years?

This drugmaker faces a key test in the next several years.

MRK : 117.42 (-1.03%)
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...

SNY : 58.06 (+1.03%)
GSK : 41.99 (-1.04%)
MRK : 117.42 (-1.03%)
MRNA : 69.68 (-0.26%)
Health Canada Approves KEYTRUDA® as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following

/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...

MRK : 117.42 (-1.03%)
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

Bristol Myers Squibb Company BMY is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been...

BMY : 49.36 (-0.76%)
PFE : 29.75 (+0.08%)
MRK : 117.42 (-1.03%)
Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

The urgent need for innovative technologies to accelerate the development of life-saving %Cancer therapies has never been more critical. With millions of lives and billions of dollars at stake, the potential...

MRK : 117.42 (-1.03%)
NVS : 116.30 (+0.28%)
KTRA : 0.1769 (+1.09%)
RKV.VN : 0.085 (unch)
RHHBY : 39.4400 (-0.43%)
XBIT : 7.52 (+0.27%)
BMRN : 71.20 (+0.08%)
AZN : 79.14 (+0.71%)
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study

Merck’s MRK stock declined 2% on Monday after Summit Therapeutics’ SMMT investigational bispecific antibody, ivonescimab, outperformed Merck’s blockbuster PD-L1 inhibitor Keytruda in a first-line...

RHHBY : 39.4400 (-0.43%)
MRK : 117.42 (-1.03%)
LLY : 905.80 (+0.09%)
SMMT : 24.22 (-1.38%)

Barchart Exclusives

Gold $3,000 is Coming. Here's How to Invest.
Western investors, through physical ETFs, are finally joining the global gold rush led by central banks, Asian investors, and wealthy investors. Holdings of physically backed gold ETFs have risen by 90.4 tons, equivalent to $7.3 billion, since May, according to data from the World Gold Council, and GLD holdings expanded for eight straight weeks, the longest run of inflows since mid-2020. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar